Management of pregnancy in HIV-infected women and prevention of mother-to-child transmission

HIV/AIDS in U.S. Communities of Color

Volumn , Issue , 2009, Pages 103-132

  Bardeguez, Arlene D ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84887263443     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-98152-9_7     Document Type: Chapter

References (176)

1. Centers for Disease Control and Prevention. HIV/AIDS surveillance report 2006;18:1-56.
2. UNAIDS. 2006 report on the global AIDS epidemic. A UNAIDS 10th anniversary special edition.
3. Centers for Disease Control and Prevention. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health care settings. MMWR 2006;55(No RR- 14):1-16.
4. Jamieson DJ, Clark J, Kourtis AP, et al. Recommendations for human immunodeficiency virus screening, prophylaxis, and treatment for pregnant women in the United States. Am J Obstet Gynecol 2007;197(Suppl 3):S26-32.
5. Centers for Disease Control and Prevention. Enhanced Perinatal Surveillance-United States, 1999-2001. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and prevention 2004:1-22. Special surveillance report 4.
6. Brooke Steele C, Lehida M-M, Campoluci R, DeLuca N, Dean H.D. Health Disparities in HIV/AIDS, Viral Hepatitis, Sexually Transmitted Diseases, and Tuberculosis: Issues, Burden, and Response, A Retrospective Review, 2000-2004. Atlanta, GA: Department of Health and Human Services, Centers for Disease Control and Prevention, November 2007. Available at: http://www.cdc.gov/nchhstp/ healthdisparities/.
7. Donegan SP, Steger KA, Lakambini R, et al. Seroprevalence of human immunodeficiency virus in parturients at Boston City Hospital: Implications for public health and obstetric practice. Am J Obstet Gynecol 1992;167:622-9.
8. Wiznia AA, Crane M, Lambert G, et al. Zidovudine use to reduce perinatal HIV type 1 transmission in an urban center. JAMA 1996;275:1504-6.
9. Sambamoorthi U, Akincigil A, McSpiritt E, et al. Zidovudine use during pregnancy among HIV-infected women on Medicaid. J Acquir Immune Defic Syndr 2002;30(4):429-39.
10. Anderson JE, Ebrahim SH, Sansom S. Women's Knowledge about treatment to prevent mother to child human immunodeficiency virus transmission. Obstet Gynecol 2004;103:165-8.
11. ACOG Committee Opinion Health Literacy. Number 391, December 2007. Obstet Gynecol 2007;110(6):1489-91.
12. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antitretroviral agents in HIV-1 infected adult and adolescents. Department of Health and Human Services. January 29, 2008;1-128. Available at http://www.aidsinfo.nih.gov.
13. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. July 8, 2008. AIDSinfo Web site (http://AIDSinfo.nih. gov).
14. Little BB. Pharmacokinetics during pregnancy: Evidence-Based maternal dose formulation. Obstet Gynecol 1999;93:858-68.
15. Tracy TS, Venkataramanan R, Glover DD, Caritis SN, for the NICHD Network of MFM units. Temporal changes in drug metabolism (CY1A2, CYP2D6 and CYP 3A activity) during pregnancy. Am J Obstet Gynecol 2005;192:633-9.
16. O'Sullivan MJ, Boyer PJ, Scott GB, Parks WP, Weller S, Blum MR, et al. The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: Phase I acquired immunodeficiency syndrome Clinical Trials Group Study (protocol 082). Am J Obstet Gynecol 1993;168(5):1510-16.
17. Mandelbrot L, Peytavin G, Firtion G, Farinotti R. Maternal-fetal transfer and amniotic fluid accumulation of lamivudine in human immunodeficiency virus-infected pregnant women. Am J Obstet Gynecol 2001;184:153-8.
18. Wang Y, Livingston E, Patil S, McKinney RE, Bardeguez A, et al. Pharmacokinetics of didanosine in antepartum and postpartum human immunodeficiency virus-infected pregnant women and their neonates: An AIDS Clinical Trials Group Study. JID 1999;180:1536-41.
19. Wade NA, Unadkat JD, Huang S, Shapiro DE, Mathias A, et al. Pharmacokinetics and safety of stavudine in HIV infected pregnant women and their infants: Pediatrics AIDS Clinical Trials Group protocol 332. The Journal of Infectious Diseases 2004;190:2167-74.
20. Brokie BM, Mirochnick M, Caparelli EV, et al., for the PACTG 1026s Study Team. Impact of pregnancy on abacavir pharmacokinetics. AIDS 2006;20(4):553-60.
21. Mirochnick M, Fenton T, Gagnier P, et al., for the Pediatric AIDS Clinical Trials Group Protocol 250 Team. Pharmacokinetics of nevirapine in human imunodeficiency virus type 1 infected pregnant women and their neonates. J Infect Dis 1998;178(2):368-74.
22. Fundaro C, Genovese O, Rendeli C, et al. Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS 2002;16(2):299-300.
23. Dear Health Care Provider. Re: Important change in Sustiva (Efavienz) package insert- Change from Pregnancy Category C to D Bristol Myers Squibb Company. March 2005.
24. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989 through 31 July 2007. Wilmington, NC: Registry Coordinating Center; 2007. Available at www.APRegistry.com.
25. Acosta EP, Zorrilla C, Van Dyke R, Bardeguez A, Smith E, et al. Pharmacokinetics of saquinavir SGC in HIV Infected pregnant women. HIV Clin. Trials 2001;2(6):460-5.
26. Stek A, Mirochnick M, Capparelli E, et al., for the Pediatric AIDS Clinical Trials Group (PACTG) 1026 Team. Reduced lopinavir exposure during pregnancy. AIDS 2006;20: 1931-9.
27. Bryson Y, Mirochnick M, Stek A, Mofenson L, et al. Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamidivine in HIV-infected pregnant women: Pediatrics AIDS Clinical Trials Group (PACTG) protocol 353. HIV Clin Trials 2008;9(2):115-25.
28. Nellen JF, Schillevoort I, Ferdinand WN, Bergshoeff AS, Godfried MH, et al. Nelfinavir plasma concentrations are low during pregnancy. CID 2004;39:736-40.
29. Van Heeswijk RP, Khaliq Y, Gallicano KE, Bourbeau M, Seguin I, et al. The pharmacokinetics of nelfinavir and M8 during pregnancy and postpartum. Clin Pharmacol Ther 2004;76:588-97.
30. Hayashi S, Beckerman K, Homma M, et al. Pharmacokinetics of indinavir in HIV-positive pregnant women. AIDS 2000;14(8):1061-2.
31. Unadkat JD, Wara DW, Hughes MD, Mathias AA, et al. Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother 2007;51(2):783-6.
32. Acosta EP, Bardeguez A, Zorrilla CD, Van Dyke R, et al., for the Pediatrics AIDS Clinical Trials Group 386 Protocol Team. Pharmacokinetics of saquinavir plus low dose ritonavir in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother 2004;48(2):430-6.
33. Ripamonti D, Cattaneo D,Maggiolo F, et al. Atazanavir plus low-dose ritonavir in pregnancy: Pharmacokinetics and placental transfer. AIDS 2007;21:2409-15.
34. Mirochnick M, Best B, Stek A, Capparelli E, et al., for the PACTG 1026s Protocol Team. Lopinavir exposure with an increased dose during pregnancy. J Acquir Immune Defic Syndr 2008;49:485-91.
35. Best B, Stek A, Hu C, et al. High dose lopinavir and standard-dose emtricitabine pharamacokinetics during pregnancy and postpartum. Abstract 629. 15th Conference on Retroviruses and Opportunistic Infections, Boston, U.S., 2008.
36. Marzolini C, Rudin C, Decosterd LA, Telenti A, et al. Transplacental passage of protease inhibitors at delivery. AIDS 2002;16:889-93.
37. Bucceri AM, Somigliana E,Matrone R, Uberti-Foppa C, Vigano P, et al. Discontinuing combination antiretroviral therapy during the first trimester of pregnancy: Insights from plasma human immunodefiency virus-1 RNA viral load and CD4 cell count. Am J Obstet Gynecol 2003;189:545-51.
38. Somigliana E, Bucceri AM, Tibaldi C, Alberico S, et al. Early invasive diagnostic techniques in pregnant women who are infected with HIV: A multicenter cases series. Am J Obstet Gynecol 2005;193:437-42.
39. Rodman J, Flynn P, Shapiro D, Bardeguez A, et al., for te PACTG 394 Study Team. Pharmacokinetics and safety of tenofovir disoproxil fumarate in HIV infected pregnant women and their infants. Abstarct 708; 13th Conference on Retroviruses and Opportunistic Infections, Denver, U.S., 2006.
40. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331(18):1173-80.
41. Stiehm ER, Lambert JS, Mofenson LM, et al. Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmne immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: Results of Pediatrics AIDS Clinical Trials Group protocol 185. J Infect Dis 1999;179:567-75.
42. Sperling R, Shapiro D, Coombs R, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med 1996;335(22):1621-9.
43. Mofenson LM, Lambert JS, Stiehm ER, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. N Engl J Med 1999;341:385-93.
44. Garcia PM. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. N Engl J Med 1999;341(6):394-402.
45. Wade NA, Birkhead GS, Warren BL, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 1998;339:1409-14.
46. Fiscus SA, Adimora AA, Schoenback VJ, et al. Trends in human immunodeficiency virus(HIV) counseling, testing and antiretroviral treatment of HIV infected women and perinatal transmission in North Carolina. J Infect 1999;180:99-105.
47. Mayaux MJ, Teglas JP, Mandelbrot L, et al. Acceptability and impact of zidovudine prevention on mother-to-child HIV-1 transmission in France. J Pediatr 1997;131:857-62.
48. Dorenbaum A, Cunningham CK, Gelber RD, et al. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission. JAMA 2002;288(2):189-98.
49. Cooper ER, Charurat M, Mofenson, L et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002;29(5):484-94.
50. The European Mode of Delivery Collaboration. Elective cesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomized clinical trial. Lancet 1999;353(9158):1035-9.
51. The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1 - A meta-analysis of 15 prospective cohort studies. N Engl J Med 1999;340(13):977-87.
52. ACOG Committee Opinion. Scheduled cesarean delivery and the prevention of vertical transmission of HIV infection. May 2000; Number 234 (219).
53. Read JS, Tuomala R, Kpamegan E, et al. Mode of delivery and postpartum morbidity among HIV-infected women: The Women and Infants Transmission Study. J Acquir Immune Defic Syndr 2001;26:236-45.
54. Marcollet A, Goffinet F, Firtion G, et al. Differences in postpartum morbidity in women who are infected with the human immunodeficiency virus after elective cesarean delivery, emergency cesarean delivery, or vaginal delivery. Am J Obstet Gynecol 2002;186:784-9.
55. Duarte G, Read JS, Gonin R, et al. Mode of delivery and postpartum morbidity in Latin America and Caribbean countries among women who are infected with human immunodeficiency virus-1: The NICHD International Site Development Initiative (NISDI) Perinatal study. Am J Obstet Gynecol 2006;195:215-29.
56. Louis J, Landon MB, Gersnoviez RJ, et al. Perioperative morbidity and mortality among human immunodeficiency virus-infected women undergoing cesarean delivery. Obstet Gynecol 2007;110:385-90.
57. Sebitloane HM, Modly J, Esterhuinzen TM. Prophylactic antibiotics for the prevention of postpartum infectious morbidity in women infected with human immunodeficiency virus: A randomized controlled trial. Am J Obstet Gynecol 2008;198:189-90.
58. Menacker F. Trends in cesarean rates for first births and repeat cesarean rates for low risk women, United States, 1990-2003. National Vital Statistics Report, Center for Disease Control and Prevention.
59. Silver RM, Landon MB, Rouse DJ, et al. Maternal morbidity associated with multiple repeat cesarean deliveries, Obstet Gynecol 2006;107:1226-32.
60. Knight M, Kurinczuk JJ, Spark P, Brocklehurst, P., for the United Kingdom Obstetrics Surveillance System Steering Committee. Cesarean delivery and peripartum hysterectomy. Obstet Gynecol 2008;111:97-105.
61. CDC. Success in implementing PHS guidelines to reduce perinatal transmission of HIVLouisiana, Michigan, New Jersey, and South Carolina, 1993, 1995 and 1996. MMWR 1998;47:688-91.
62. Bulterys M, Jamieson DJ, O'Sullivan MJ, et al. Rapid HIV-testing during labor: A multicenter study. JAMA 2004;292:219-23.
63. Jamieson DJ, Cohen MH, Maupin R, et al. Rapid human immunodeficiency virus-1 testing on labor and delivery in 17 U.S. hospitals: the MIRIAD experience. Am J Obstet Gynecol 2007;197(Suppl 3):S72-82.
64. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistence mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001;15(15):1951-7.
65. Cunningham CK, Chaix M, Rekaccwicz C, et al. Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: A substudy of Pediatric AIDS Clinical Trials Group Protocol 316. J Infect Dis 2002;186:181-8.
66. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med. 2004;315(3):229-39.
67. Lockman S, Shapiro RL, Smeaton LM, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 2007;356:135-47.
68. Coffie PA, Ekouevi DK, Chaix M, et al.Maternal 12 month response to antiretroviral therapy following prevention of mother-to -child transmission of HIV type1, Ivory Coast, 2003- 2006. Clin Infect Dis 2006;46:611-2.
69. Chaix M, Ekouevi DK, Rouet F, et al. Low risk of nevirapine resistance mutations in the prevention of mother to child transmission of HIV: Agence Nationale de Recherches sur le SIDa Ditrame Plus, Abidjan, Cote d'Ivorie. J Infect Dis 2006;193:482-7.
70. Chi B, Sinkala M, Mbewe F, et al. Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine foe perinatal HIV prevention: An open-label randomized trial. Lancet 2007;370:1698-705.
71. Lo WY, Friedman JM. Teratogenicity of recently introduced medications in human pregnancy. Obstet Gynecol 2002;100:465-73.
72. Andrade SE, Gurwitz JH, Davis RL, Chan KA, Finkelstein JA, et al. Prescription use in pregnancy. Am J Obstet Gynecol 2004;191:398-407.
73. Newschaffer CJ, Cocroft J, Anderson CE, et al. Prenatal zidovudine use and congenital anomalies in a Medicaid population. J Acquir Immune Defic Syndr 2000;24:249-56.
74. Watts HD, Covington DL, Beckerman K, Garcia P, Scheuerle A, et al. Asssesing the risk of birth defects associated with antiretroviral exposure during pregnancy. Am J Obstet Gynecol 2004;191:985-92.
75. Watts HD, Li D, Handlelsman E, et al. Assessment of birth defects according to maternal therapy among infants in the women and Infants transmission study. J Acquir Immune Defic Syndr 2007;44(3):299-305.
76. Covington DL, Conner SD, Doi PA, Swinson J, Daniels EM. Risk of birth defects associated with nelfinavir exposure during pregnancy. Obstet Gynecol 2004;103:1181-9.
77. European Collaborative study. Exposure to antiretroviral therapy in utero or early life: The health of uninfected children born to HIV-infected women. J Acquir Immune Defic Syndr 2003;32:380-7.
78. Sperling RS, Shapiro DE, McSherry GD, et al. Safety of the maternal-infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 076 Study. AIDS 1998;12:1805-13.
79. Bardeguez A, Shapiro D, Mofenson LM, et al. Effect of cessation of zidovudine prophylaxis to reduce vertical transmission on maternal disease progression and survival. J Acquir Immune Defic Syndr 2003;32:170-81.
80. Watts DH, Lambert JS, Stiehm ER, Harrris R, et al., for the Pediatric AIDS Clinical Trials Group 185 Study Team. Progression of HIV disease among women following delivery. J Acquir Immune Defic Syndr 2003;33:585-93.
81. Minkoff H, Ahdieh L, Watts H, Greenblatt RM, et al. The relationship of pregnancy to the use of highly active antiretroviral therapy. Am J Obstet Gynecol 2001;184:1221-7.
82. Watts DH, Rajalakshmi B,Maupin R, Delke I, et al.Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316. Am J Obstet Gynecol 204;190:506-16.
83. Zorrilla CD, Van Dyke R, Bardeguez A, Acosta E, et al., for the Pediatrics AIDS Clinical Trials Group 386 Protocol Team. Clinical response, safety and tolerability to saquinavir with low-dose ritonavir in HIV-1 infected mothers and their infants. Antimicrob Agents Chemother 2007:2208-10.
84. Tuomala RE, Watts H, Li D, et al. Improved obstetrics outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy. J Acquir Immune Defic Syndr 2005;38:449-73
85. Bristol-Myers Squibb Company. Healthcare provider important drug warning letter. January 5, 2001.
86. Hitti J, Frenkel LM, Stek AM, et al. Maternal toxicity with continuous nevirapine in pregnancy results from PACTG 1022. J Acquir Immune Defic Syndr 2004;36:772-6.
87. Timmermans S, Templlman C, Godfried MH, et al. Nelfinavir and nevirapine side effects during pregnancy. AIDS 2005;19:795-9.
88. Joy S, Poi M, Hughes L, et al. Third trimester maternal toxicity with nevirapine use in pregnancy. Obstet Gynecol 2005;106:1032-8.
89. Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999;354:1084-9.
90. The Perinatal Safety Review Working Group. Nucleoside exposure in the children of HIVinfected women receiving antiretroviral drugs: Absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts. JAIDS 2000;25(3):261-8.
91. CulnaneM, FowlerM, Lee SS, et al. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. JAMA 1999;281:151-7.
92. Hanson IC, Antonelli TA, Sperling RS, et al. Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine. J Acquir Immune Defic Syndr 1999;20(5):463-7.
93. Webster Dictionary, 3rd College Edition.
94. Osterberg L, Blaschke T. Adherence to medications. N Eng J Med 2005;353:487-97.
95. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000;14(4):357-66.
96. Ross L, Lim ML, Liao Q, et al. Prevalence of antiretrovirak drug resistance and resistance associated mutations in antiretroviral naïve HIV infected individuals from 40 United States cities. HIV Clin Trials 2007;8:1-8.
97. Johnson VA, Petropoulos CJ, Woods CR, et al. Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant. J Infect Dis 2001;183:1688-93.
98. Paterson DL, Swindells S, Mohr JA, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30.
99. Murphy DA, Wilson CM, Durako SJ, et al. Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the U.S. AIDS Care 2001;13:27-40.
100. Lucas GM, Cheever LW, Chaison RE, et al. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr 2001;71:251-9.
101. Starace F, Ammassari A, Trotta MP, et al. Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002;3(Suppl 3):S136-9.
102. Cohn SE, Umbleja T, Mrus J, Bardeguez AD, Anderson J, Chesney MA. Prior illicit drug use and missed prenatal vitamins predict non-adherence to antiretroviral therapy in pregnancy: Adherence analysis A5084. AIDS Patient Care STDs 2008;22(1):29-40.
103. Bardeguez A, Lindsey JC, Shannon M, et al. Adherence to antiretrovirals (arvs) in U.S. women during and after pregnancy. J Acquir Immune Defic Syndr 2008;48(4):408-17.
104. Wilson T, Ickovics JR, Fernandez MI, et al., for the Perinatal Guidelines Evaluation Project. Self-reported zidovudine adherence among pregnant women with human immunodeficiency virus infection in four U.S. states. Am J Obstet Gynecol. 2001;184(6):1235-40.
105. Ickovics JR, Wilson TE, Royce RA, et al. Prenatal and postpartum zidovudine adherence among pregnant women with HIV: Results of a MEMS sub-study from the perinatal guidelines evaluation project. J Acquir Immune Defic Syndr 2002;30(3):311-5.
106. van den Broek NR, White SA, Neilson JP. The relationship between asymptomatic human immunodeficiency virus infection and the prevalence and severity of anemia in pregnant Malawian women. Am J Trop Med Hyg 1998;59:1004-7.
107. Henry DH, Volberding PA, Leitz G. Epoetin alfa for the treatment of anemia in HIV-infected patients. J Acquir Immune Defic Syndr 2004;37:1221-7.
108. Sullivan PS, Hanson D, Chu SY, et al. Surveillance for thrombocytopenia in persons infected with HIV: Results from the multistate adult and adolescent spectrum of disease project. J Acquir Immune Defic Syndr 1997;14:374-9.
109. Miguez-Burbano MJ, Jackson J, Hadrigan S. Thrombocytopenia in HIV disease: Clinical relevance, pathophysiology and management. Curr Med Chem-Cardiovasc Hematol Agents 2005;3:365-76.
110. Thrombocytopenia in Pregnancy. ACOG practice bulletin. Clinical management guidelines for obstetrician-gynecologist. Number 6, September 1999. In ACOG 2008 Compendium of Selected Publications. Volume 2: Practice Bulletins, pp. 581-91.
111. Duration of rupture membranes and vertical transmission of HIV-1: A meta-analysis from 15 prospective cohort studies. The International Perinatal group. AIDS 2001;15:357-68.
112. Minkoff H, Burns DN, Landesman S, et al. The relationship of the duration of ruptured membranes to vertical transmission of human immunodeficiency virus type. Am J Obstet Gynecol 1995;173:585-9.
113. Landesman SH, Kalish LA, Burns DN, et al. Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child. N Engl JMed 1996;34:1617-23.
114. ACOG Committee Opinion Prevention of Early Onset Group B Streptococcal Disease in Newborns. Number 279. December 2002. In ACOG 2008 compendium of selected publications. Volume 1: Committee opinions and policy statements, pp. 425-32.
115. Premature Rupture of Membranes. ACOG practice bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 80, April 2007. In ACOG 2008 compendium of selected publications. Volume 2: Practice Bulletin, pp. 940-52.
116. Major CA, Towers CV, Lewis DF, and Garite TJ. Expectant management of preterm premature rupture of membranes complicated by active recurrent genital herpes. Am J Obstet Gynecol 2003;188:1551-5.
117. Drake AL, John-Steward GC, Wald A, et al. Herpes Simplex virus type 2 and Risk of intrapartum human immunodeficiency virus transmission. Obstet Gynecol 2007;109:403-9.
118. Alvarez JR, Bardeguez A, Iffy L, Apuzzio J. Preterm premature rupture of membraines in pregnancies complicated by human immunodeficiency virus infection: A single center's fiveyear experience. J Matern-Fetal Neonat Med 2007;20:853-7.
119. Lorenzi P, Spicher VM, Laubereau B, et al. Antiretroviral therapies in pregnancy: Maternal, fetal, and neonatal effects. Swiss HIV Cohort Study, The Swiss Collaborative HIV and Pregnancy Study, and The Swiss Neonatal HIV Study. AIDS 1998;12(18):F241-7.
120. Morris AB, Cu-Uvin S, Harwell JI, et al. Multicenter review of protease inhibitors in 89 pregnancies. J Acquir Immune Defic Syndr 2000;25:306-11.
121. Cotter AM, Gonzalez A, Duthely LM, et al. Is antiretroviral therapy during pregnancy associated with increased risk of preterm delivery, low birth weight, or stillbirth? J Infect Dis 2006;193:1195-201.
122. Tuomala RE, Shapiro DE, Mofenson LM, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med 2002;346(24):1863- 70.
123. Grosch-Woerner I, Puck K, Maier RF, et al. Increased rate of prematurity associated with antenatal antiretroviral therapy in a German/Austrian cohort of HIV-1-infected women. HIV Med 2008;9:6-13.
124. Schulte J, Dominguez K, Sukalac T, et al. Declines in low birth weight and preterm among infants who were born to HIV-infected women duringan era of increased use of maternal antiretrovital drugs: Pediatric spectrum of HIV disease, 1989-2004. Pediatrics 2007;119:e 900-6.
125. Martin F, Taylor GP. Increased rates of preterm delivery are associated with the initiation of highly active antiretroviral therapy during pregnancy: A single center cohort study. JID 2007;196:558-61.
126. Ravizza M, Martinelli P, Bucceri A, et al. Treatmment with protease inhibitors and coinfection with hepatitis C virus are independent predictors of preterm delivery in HIV-1 infectedpregnant women. JID 2007;195:913-4.
127. Kourtis AP, Schmid CH, Jamieson DJ, Lau J. Use of antiretroviraltherapy in pregnant HIVinfected women and the risk of premature delivery: A meta analysi. AIDS 2007;21:607-15.
128. Szyld EG, Warley EM, Freimanis L, et al. Maternal antiretroviral drugs during pregnancy and infant lowbirthweight and preterm birth. AIDS 2006;20:2345-53.
129. Beitune PA, Duarte G, FossM,Montenegro RM, et al. Effect of maternal use of antiretroviral agents on serum insulin levels of the newborn infant. Diabetes Care 2005;28:856-9.
130. Chamait R, franklin P, Spector SA, Hull AD. Protease inhibitors and decreased birth weight in HIV infected pregnant women with impaired glucose tolerance. J Perinatol 2002;22:370-3.
131. Justman JE, Benning L, Danoff A, Minkoff H, et al. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. JAIDS 2003;32:298-302.
132. Gestational Diabetes. ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 30, September 2001. In ACOG 2008 compendium of selected publications. Volume 2: Practice Bulletin, pp. 695-708.
133. Dinsmoor MJ, Forrest ST. Lack of an effect of protease inhibitor use on glucose tolerance during pregnancy. Infect Dis Obstet Gynecol 2002;10:187-91.
134. Hitti J, Anderson J, McComsey G, et al., for the AIDS Clinical Trials Group 5084 Study Team. Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS Clinical Trials Group A5084. Am J Obstet Gynecol 2007;196:331.e1-7.
135. Watts DH, Balasubraman R, Maupin ET, et al. Maternal toxicity and pregnancy complications in HIV-infected women receiving antiretroviral therapy: PACTG 316. Am J Obstet Gynecol 2004;190:506-16.
136. Hollingsworth DR, Moore TR. Diabetes and pregnancy Chapter 46. In Maternal Fetal Medicine: Principles and Practice. Creasy RK, Resnick R, editors, 1989, 2nd ed., p. 835.
137. Brizzi P, Tonolo G, Esposito F, et al. lipoprotein metabolism during normal pregnancy. Am J Obstet Gynecol 1999;181:430-4.
138. Fahraeus L, Larsson-Cohn U,Wallentin L, et al. Plasma lipo-proteins including high density lipoproteins sub-fractions during normal pregnancy. Obstet Gynecol 1985;66:468-72.
139. Livingston E, Cohn SE, Yang Y, et al., for the AIDS Clinical Trials Group A5084 Study team. Lipids & lactate in HIV-1 infected pregnancies with/without protease inhibitor-based therapy. Obstet Gynecol 2007;110:391-7.
140. DeVore GR, Romero R. Genetic sonography: An option for women of advanced maternal age with negative triple-marker maternal serum screening results. J Ultrasound Med 2003;22:1191-9.
141. Pinette MG, Egan JFX, Wax JR, et al. Combined sonographic and biochemical markers for down syndrome screening. J Ultrasound Med 2003;22:1185-90.
142. Biggio JR, Morris C, Owen J, Stringer JS. An outcome analysis of five prenatal screening strategies for trisomy 21 in women younger than 35 years. Am J Obstet Gynecol 2004;190:721-9.
143. Hobbins JC, Lezotte DC, Persutte WH, et al. An 8-center study to evaluate the utility of midterm genetic sonograms among high risk pregnancies. J Ultrasound Med 2003;22:33-8.
144. (a) Coll O, Suy A, Hernandez S, et al. Prenatal diagnosis in human immunodeficiency virus-infected women: A new screening program for chromosomal anomalies. Am J Obstet Gynecol 2006;194:192-8.
145. (b) Mandelbrot L, Jasseron C, Ekoukou D, et al., for the ANRS French Perinatal Cohort. Ammniocentesis and mother to child human immunodeficiency virus transmission in the Agence Nationale de Reserches sur le Sida et les Hepatites Virales French Perinatal Cohort. Am J Obstet Gynecol 2009;200:160.e1-9.
146. Gross S, Castillo W, Crane M, et al. Maternal serum alpha fetoprotein and human chorionic gonadotropin levels in women with HIV. Am J Obstet Gynecol 2003;188:1052-6.
147. Yudin MH, Prosen TL, Landers DV. Multiple marker screening in HIV positive pregnant women: Screen positivity rates with the triple and quad screen. Am J Obstet Gynecol 2003;189:973-6.
148. Einstein FH, Wright RL, Trentacoste S, et al. The impact of protease inhibitors on maternal serum screening analyte levels in pregnant women who are HIV positive. Am J Obstet Gynecol 2004;191:1004-8.
149. Shapiro DE, Sperling RS, Mandelbrot L, et al. Risk factors for perinatal human immunodeficiency transmission in patients receiving zidovudine prophylaxis. PACTG Protocol 076 Study Group. Obstet Gynecol 1999;94:897-908.
150. Mandelbrot L, Mayaux MJ, Bongain A, et al. Obstetrics factors and mother-to-child transmission of human immunodeficiency virus type1: The French Perinatal Cohorts. Am J Obstet Gynecol 1996;175:661-7.
151. Bucceri AM, Somigliana E, Vignali M. Early invasive diagnostic techniques during pregnancy in HIV-infected women. Acta Obstet Gynecol Scan 2001;80:82-3.
152. The European Collaborative Study. Fluctuations in symptoms in human immunodeficiency virus-infected children: The first 10 years of life. Pediatrics 2001;108:116-22.
153. Gortmaker SL, Hughes M, Cervia J, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med 2001;345:1522-28.
154. Resino S, Bellon JM, Resino R, Navarro L, et al. Extensive implementation of highly active antiretroviral therapy shows great effect on survival and surrogate markers in vertically HIVinfected children. CID 2004;38:1605-12.
155. Zorrilla C, Febo I, Ortiz I, et al. Pregnancy in perinatally HIV-infected adolescents and young adults - Puerto Rico, 2002. MMWR Weekly 2003;52:149-51.
156. Brogly SB, Watts DH, Ylitalo N, et al. Reproductive health of adolescent girls perinatally infected with HIV. Am J Public Health 2007;97:1047-52.
157. Fraser AM, Brockert JE, Ward RH. Association of young maternal age with adverse reproductive outcomes. N Engl J Med 1995;332:1113-7.
158. Jolly MC, Sebire N, Harris J, Robinson S, Regan L. Obstetric risks of pregnancy in women less than 18 years old. Obstet Gynecol 2000;96:962-6.
159. Chen XK,Wen SW, Fleming N, Demissie K, Rhoads GG,WalkerM. Teenage pregnancy and adverse birth outcomes: A large population based retrospective cohort study. Int J Epidemiol 2007;36:368-73.
160. Williams S, Keane M, Bettica L, Dieudonne A, Bardeguez A. Adeherence issues and viral suppression in perinatally-infected pregnant adolescents. Infectious Disease Society for Obstetrics and Gynecology. 34th Annual Scientific Meeting, Boston, MA, August 9, 2007.
161. Williams S, Keane M, Bettica L, Dieudonne A, Bardeguez A. Pregnancy outcomes in young women with perinatally acquired human immunodeficiency virus-1. Am J Obstet Gynecol 2009;200:149.e1-5.
162. McConnell M, Clark H, Zorrilla C, et al. Pregnancy in perinatally HIV-infected youth. 3rd IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, Brazil, July 24-27, 2005. Abstract number: MoPeLB9.5C01.
163. Sharma A, Feldman JG, Golub ET, et al. Live birth patterns among human immunodeficiency virus-infected women before and after the availability of highly active antiretroviral therapy. Am J Obstet Gynecol 2007;196:541.e1-6.
164. Hawes SE, Critchlow CW, Faye MA, et al. Increased risk of high grade cervical squamous intraepithelial lesions and invasive cancer among African women with human immunodeficiency virus type 1 and 2 infections. J Infect Dis 2003;188:55-63.
165. Jakobson M, Gissler M, Sainio S, et al. Preterm delivery after surgical treatment for cervical intraepithelial neoplasia. Obstet Gynecol 2007;109:309-13.
166. Moscicki A, Ellenberg JH, Crowley-Nowick P, et al. Risk of high-grade squamous intraepithelial lesion in HIV infected adolescents. JID 2004;190:1413-21.
167. Viral Hepatitis in Pregnancy. ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 86, October 2007. Obstet Gynecol 2007;110(4):941-55.
168. Santiago-Munoz P, Scott R, Sheffield J, et al. Prevalence of hepatitis B and C in pregnant women who are infected with human immunodeficiency virus. Am J Obstet Gynecol 2005;193:1270-3.
169. Chen JL, Phillips KA, Kanouse DE, Collins RL, Miu A. Fertility desires and intentions of HIV-positive men and women. Family Planning Perspect 2001;33(4):144-52.
170. Bedimo-Rung AL, Clark RA, Dumestre J Rice J, Kissinger P. Reproductive decision-making among HIV-infected women. J Nat Med Assoc 2005;97:1403-10.
171. Klein J, Pena JE, Thornton II MH, Sauer MV. Understanding the motivations, concerns and desires of human immunodefiviency virus 1 serodiscordant couples wishing to have children through assisted reproduction. Obstet Gynecol 2003;101:987-94.
172. Massad LS, Springer G, Jacobson L, et al. Pregnancy rates and predictors on conception. Miscarriage and abortion in U.S. women with HIV. AIDS 2004;18:281-6.
173. Blair JM, Hanson DL, Jones JL, Dworkin MS. Trends in pregnancy rates among women with human immunodeficiency virus. Obstet Gynecol 2004;103:663-8.
174. Goldman-Clery J, Pena JE, Thornton MH, et al. Obstetrics outcomes of human immunodeficiency virus 1 serodiscordant couples following in vitro fertilization with intracytoplasmic sperm injection. Am J Perinatol 2003;29:305-11.
175. Al-Khan A, Colon J, Palta V, Bardguez A. Assisted Reproductive technology for men and women infected with human immunodeficiency virus type 1. CID 2003;36:195-200.
176. Lyerly AD, Anderson J. Human immunodeficiency virus and assisted reproduction: reconsidering evidence, reframing ethics. Fertil Steril 2001;75:843-58.